EVRY, France--(BUSINESS WIRE)--IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced a collaboration with investigators from the New EPOC study to validate the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy.
Help employers find you! Check out all the jobs and post your resume.
